Literature DB >> 28810573

Warfarin-induced life-threatening bleeding associated with a CYP3A4 loss-of-function mutation in an acute limb ischemia patient: Case report and review of the literature.

Xiao-Wei Ma1, Chang-Ning Hao2, Zhi-Chun Gu3, Meng Ye2, Min Li1, Lan Zhang2.   

Abstract

Patients with acute limb ischemia, deep venous thrombosis and pulmonary artery embolism may be treated with warfarin. The dose-response interaction of warfarin is associated with numerous factors, depending on which an uncommon life-threatening bleeding may occur. The present case study reported on a patient with acute limb ischemia and a history of warfarin-induced bleeding ten years previously and who again developed life threatening bleeding associated with warfarin treatment and received vascular surgery. In this patient, a cytochrome P450 3A4 loss-of-function mutation decreased the effective dose of warfarin. Although this was a rare case, clinicians should be alert to the bleeding risk associated with such rare genetic mutations.

Entities:  

Keywords:  acute limb ischemia; case report; genetic mutation; warfarin

Year:  2017        PMID: 28810573      PMCID: PMC5525648          DOI: 10.3892/etm.2017.4604

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  19 in total

1.  Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.

Authors:  Sheng-Wen Huang; Hai-Sheng Chen; Xian-Qun Wang; Ling Huang; Ding-Li Xu; Xiao-Jia Hu; Zhi-Hui Huang; Yong He; Kai-Ming Chen; Dao-Kang Xiang; Xiao-Ming Zou; Qiang Li; Li-Qin Ma; Hao-Fei Wang; Bao-Lin Chen; Liang Li; Yan-Kai Jia; Xiang-Min Xu
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

2.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

Review 3.  The role of dietary vitamin K in the management of oral vitamin K antagonists.

Authors:  Michael V Holmes; Beverley J Hunt; Martin J Shearer
Journal:  Blood Rev       Date:  2011-09-13       Impact factor: 8.250

Review 4.  Fever as a risk factor for increased response to vitamin K antagonists: a review of the evidence and potential mechanisms.

Authors:  Timothy H Self; Carrie S Oliphant; Anne B Reaves; Amy M Richardson; Christopher W Sands
Journal:  Thromb Res       Date:  2014-10-22       Impact factor: 3.944

Review 5.  The pharmacogenetics of the response to warfarin in Chinese.

Authors:  May P S Lam; Bernard M Y Cheung
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

6.  Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.

Authors:  Rui Liu; Zi-Yi Zhou; Yi-Bei Chen; Jia-Li Li; Wei-Bang Yu; Xin-Meng Chen; Min Zhao; Yuan-Qi Zhao; Ye-Feng Cai; Jing Jin; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

7.  Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.

Authors:  Manuela Vecsler; Ronen Loebstein; Shlomo Almog; Daniel Kurnik; Boleslav Goldman; Hillel Halkin; Eva Gak
Journal:  Thromb Haemost       Date:  2006-02       Impact factor: 5.249

8.  Warfarin dosage response related pharmacogenetics in Chinese population.

Authors:  Siyue Li; Yuangao Zou; Xia Wang; Xunbei Huang; Yong Sun; Yuqing Wang; Li Dong; Hong Jiang
Journal:  PLoS One       Date:  2015-01-16       Impact factor: 3.240

9.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

10.  Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.

Authors:  Ajay K Kakkar; Iris Mueller; Jean-Pierre Bassand; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y H Lip; Lorenzo G Mantovani; Alexander G G Turpie; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W A Verheugt
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.